FOXO1A is a target for HER2-overexpressing breast tumors.
about
Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic miceInhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppressionIGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion.MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathwayThe differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway.Heparan sulfate mediates trastuzumab effect in breast cancer cellsTriple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancerMechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanismLoss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression.Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axisAnti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Obesity, energy balance, and cancer: new opportunities for preventionAnti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.Role of Forkhead Box Class O proteins in cancer progression and metastasis.miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis.Flotillins as regulators of ErbB2 levels in breast cancer.Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells.Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.Protein biomarkers for subtyping breast cancer and implications for future research.FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer.
P2860
Q33612060-B3D6047B-0C04-4852-ADBE-4DE45634DB6CQ33688434-C1007AF0-F2EE-478D-95D4-ED250FFBA810Q33952555-8021547D-17A0-4390-97B6-936E730A9901Q34622404-3C730E6A-E82B-46D7-B053-ECDF1A5844EAQ34746718-2D0D6252-5AA0-4441-9C81-8ABFABC72246Q35003529-0EBFFDE5-D513-4A6B-A57A-4D33B7124BF1Q35027892-BF13575D-A835-42E7-82F0-903ED73CFC4CQ35058975-CD136E05-38F9-4C49-8CAB-FFF47614436AQ35609443-8C884780-A054-4834-A919-EE727BCAD14BQ35624814-9755C854-0286-407E-921D-E52EA3B67782Q35841978-E643515D-7D06-4B61-929E-AAEE285ED29FQ36287390-D0CCB5AE-B5DC-4B08-9622-CAEB9C39C384Q36629588-5FF26465-6DBF-4366-AA11-FF5D9774D329Q36670915-E0C1C4AC-54BE-4432-AF5A-ABA0FDAC1513Q36810924-B2A6F9D0-5231-4938-8D11-8E366060C335Q36879470-51A73D89-F2A4-4D67-B40E-F6D185BF8816Q37066536-B9C86245-2F79-4C36-A348-6F6240A015FEQ37194856-35909CB3-5261-4EB5-8D47-EF6910455470Q38302045-FC7792D8-A1CC-4AB8-8CE6-087C8308CC0EQ38647185-11EC03AE-7C96-4921-98A1-78E84C49BE60Q38873436-5A4AC144-2946-4FFE-958A-F1E968CCF1B5Q39003526-EC9B5C0F-039B-4D68-9746-DFE4BEA3EBD9Q39301423-A85CAA21-AC6E-4598-8E92-EA0518548413Q41811402-78BA1B53-5F15-4B94-B669-FDAB5477CB46Q41846641-07D0CF9D-4F1B-43DB-B722-523871A2389EQ47261659-B478E6EB-7F75-475A-80A2-65204FDDF60FQ48806131-0868967F-C4A5-4EDB-B6F9-C5B14E2C3A1DQ49357675-49DAD727-4A23-428C-BA25-195DA7DE25A1
P2860
FOXO1A is a target for HER2-overexpressing breast tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
FOXO1A is a target for HER2-overexpressing breast tumors.
@ast
FOXO1A is a target for HER2-overexpressing breast tumors.
@en
type
label
FOXO1A is a target for HER2-overexpressing breast tumors.
@ast
FOXO1A is a target for HER2-overexpressing breast tumors.
@en
prefLabel
FOXO1A is a target for HER2-overexpressing breast tumors.
@ast
FOXO1A is a target for HER2-overexpressing breast tumors.
@en
P2093
P2860
P1433
P1476
FOXO1A is a target for HER2-overexpressing breast tumors.
@en
P2093
Dennis Slamon
Jaydutt V Vadgama
Marianna Sarkissyan
Xiying Shang
Yanyuan Wu
P2860
P304
P356
10.1158/0008-5472.CAN-10-0176
P407
P577
2010-06-15T00:00:00Z